Kinase-independent role for CRAF-driving tumour radioresistance via CHK2
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Kinase-independent role for CRAF-driving tumour radioresistance via CHK2
Authors
Keywords
-
Journal
Nature Communications
Volume 6, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-09-03
DOI
10.1038/ncomms9154
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- An integrin β3–KRAS–RalB complex drives tumour stemness and resistance to EGFR inhibition
- (2014) Laetitia Seguin et al. NATURE CELL BIOLOGY
- RAF Inhibitors Activate the MAPK Pathway by Relieving Inhibitory Autophosphorylation
- (2013) Matthew Holderfield et al. CANCER CELL
- Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway
- (2013) Xiao-Fang Dai et al. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
- Concurrent versus Sequential Sorafenib Therapy in Combination with Radiation for Hepatocellular Carcinoma
- (2013) Aaron T. Wild et al. PLoS One
- Identification of Novel Gene Targets and Functions of p21-Activated Kinase 1 during DNA Damage by Gene Expression Profiling
- (2013) Mona Motwani et al. PLoS One
- MYC Regulation of CHK1 and CHK2 Promotes Radioresistance in a Stem Cell-like Population of Nasopharyngeal Carcinoma Cells
- (2012) W.-J. Wang et al. CANCER RESEARCH
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- A MEK-independent role for CRAF in mitosis and tumor progression
- (2011) Ainhoa Mielgo et al. NATURE MEDICINE
- Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells
- (2011) C. C. Ong et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFR /B-RAF
- (2010) E. A. Murphy et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ras/Raf-1/MAPK Pathway Mediates Response to Tamoxifen but not Chemotherapy in Breast Cancer Patients
- (2009) L. M. McGlynn et al. CLINICAL CANCER RESEARCH
- Cellular Inhibition of Checkpoint Kinase 2 (Chk2) and Potentiation of Camptothecins and Radiation by the Novel Chk2 Inhibitor PV1019 [7-Nitro-1H-indole-2-carboxylic acid -amide]
- (2009) A. G. Jobson et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Clinical target promiscuity: lessons from ras molecular trials
- (2008) Ramesh Rengan et al. CANCER AND METASTASIS REVIEWS
- p21 activated kinase 5 activates Raf-1 and targets it to mitochondria
- (2008) Xiaochong Wu et al. JOURNAL OF CELLULAR BIOCHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started